Gland Pharma Limited announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with an undisclosed global pharmaceutical company, disclosed pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015.
The partnership establishes Gland Pharma as an integrated end-to-end CDMO partner for technology transfer, manufacturing, and supply of a portfolio of sterile injectable products for global markets. The agreement follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply.
The product portfolio comprises 55 SKUs across both oncology and non-oncology products in various presentations including Vial, Lyo (lyophilized), Ampoules, and pre-filled syringes (PFS), covering both complex and conventional injectable formulations.
Financial Impact and Timeline
The agreement is expected to provide strong long-term business visibility with revenue generation anticipated from calendar year 2029. Once all products are commercialized, the annualized revenue potential is estimated to be approximately USD 90-100 million. Technology transfer activities are planned for completion within two years.
Manufacturing and Operational Details
The products will be manufactured across three of Gland Pharma's sites. There is scope for adding more products to the agreement in the future. The company will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive "one-stop" solution.
Management Commentary
Mr. Srinivas Sadu, Executive Chairman, stated that the partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's capabilities and provides meaningful long-term revenue visibility. He emphasized the company's commitment to investing in capabilities and capacity to support the partner's evolving needs.
Company Background
Gland Pharma, established in 1978 in Hyderabad, operates primarily under a CDMO & business-to-business (B2B) model with a global footprint across 60 countries including the United States, Europe, Canada, Australia, and India. The company has expertise in developing, manufacturing, and marketing sterile injectables.